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ABSTRACT
Objective: The aim of this study was to develop transferosome vesicles for the transdermal drug delivery of lynestrenol.
Methods: The lynestrenol transferosome vesicle was made by encapsulating the drug in a variation of phosphatidylcholine and Tween 80 by the thin-
layer hydration method. The resulting transferosome vesicles were modified with a time variation of 30, 60, 90, and 120 min, and sonication variations 
were paused and not paused. Particle size evaluation, polydispersity (PDI), and entrapment efficiency (%EE) were carried out on the variation of 
sonication time.
Results: The evaluation results showed that sonication without pauses showed better %EE and particle size than sonication with pauses and 
increasing concentration of Tween 80 (edge activator). The %EE increased, and particle size decreased with increasing sonication time; PDI of vesicles 
was heterogeneous with increasing sonication time. The %EE in formulas F1 and F2 after 120 min was 73.06% and 76.06% (paused) and 80.40% and 
82.97% (without paused). The particle size of formula F1 and F2 after 120 min 575.4 nm and 471.6 nm (paused) and 524.1 nm and 434.7 nm (without 
paused). The PDI formulas of F1 and F2 after 120 min were 0.69 and 0.763 (paused) and 0.84 and 0.59 (without paused).
Conclusion: Based on the results of the transferosome vesicle characteristics, it was shown that the optimal vesicle composition for packaging 
lynestrenol was vesicles that were composed of phosphatidylcholine and Tween 80 without pauses and could potentially be used as a transdermal 
drug delivery system.
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INTRODUCTION
The stratum corneum, the outermost barrier of the skin which provides 
protection against the entry of foreign materials, imposes an obstacle 
to the transdermal diffusion of drugs [1]. Since only a few small-
molecule drugs with high lipophilicity can naturally permeate through 
the hydrophobic stratum corneum, a vast majority of hydrophilic 
drugs have been ruled out against transdermal delivery. Even after 
the drug successfully penetrates the stratum corneum, it may be 
degraded prematurely by epidermal enzymes, resulting in decreased 
bioavailability. Latency in the onset of action as well as a lack of 
pharmacokinetic control may also undermine the reliability of the 
transdermal delivery. One transdermal formulation that may overcome 
some of these obstacles is the transferosome [2].
Transferosomes for potential transdermal application contain a 
mixture of lipids and biocompatible membrane softeners. The optimal 
mixture leads to flexibility of the elastic liposomal membranes and to 
the possibility of penetration through channels of the skin which are 
opened by the carriers. Transferosome is a supramolecular entity that 
can pass through a permeability barrier and thereby transport material 
from the application site to the destination site. Transferosome is more 
elastic than standard liposomes and therefore is used as a novel carrier 
for effective transdermal drug delivery [3,4].
These nanoparticles have been advocated as one potential delivery 
system, which can resolve the skin permeation limitation of drugs to a 
great extent. The likelihood of nanoparticle penetration across the skin 
has recently been reviewed by the Scientific Committee on Consumer 
Products in relation to dermal exposure [4,5]. The very small particles 
of less than 100 nm, such as functionalized fullerenes and quantum 
dots, can penetrate into the viable tissues of a skin. The metallic and 
quantum dot nanoparticles greater than 200 nm can also penetrate 
through the stratum corneum and into the viable epidermis [6,7].
MATERIALS AND METHODS
Materials
Lynestrenol was purchased from IPC Pirumadara (India); Tween 80 and 
Phospholipon® 90G (Soya phosphatidylcholine ≥91%) were purchased 
from Lipoid (GMBH, Jerman); cholesterol, potassium dihydrogen 
phosphate monohydrate, sodium hydroxide, and dichloromethane were 
purchased from Merck (Darmstadt, German). Methanol and acetonitrile 
were of analytical grade and were purchased from Jakarta, Indonesia.
Methods
Preparation of transferosomes
The thin-film hydration method was used for the preparation of the 
vesicles. The lipid Phospholipon® 90G and edge activator Tween 80 
were employed for the formulation of the vesicles. For the formulation of 
vesicles, soya phosphatidylcholine, cholesterol, and Tween 80 at different 
concentrations were selected as the lipid, membrane stabilizer, and edge 
activator, respectively. The lipid, edge activator, and drug (lynestrenol) 
were weighed and then dissolved in dichloromethane. This solution was 
evaporated on a rotary evaporator (Buchi R-100, Switzerland) at 40°C 
with a vacuum evaporator on 850 mbar (Buchi V-100, Switzerland) until 
became thin-layer film. Nitrogen gas was allowed to flow through the 
thin film, and it was then stored in the refrigerator for 24 h. The thin film 
was then hydrated with pH 7.4 phosphate-buffered saline (PBS) [8,9]. 
The formulas of the different transferosomes are shown in Table 1.
Sonication of the formulas
The prepared transferosomes were sonicated with a state of amplitude 
of 100, time 10 min, and pulse 3 (amp/time/pulse=100/10/3). 
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Transferosomes of the four formulas were sonicated without intervals 
of 30, 60, 90, and 120 min and sonicated with intervals of 15 min every 
30, 60, 90, and 120 min. The results of each time are paused and without 
paused in measuring particle size, zeta potential, polydispersity (PDI), 
and adsorption efficiency [9].
Particle size, PDI index, and zeta potential measurements
Zeta potential, PDI index, and particle size for each transferosome 
formula were determined using dynamic light scattering techniques at 
25°C using the particle size system, (Zetasizer, Malvern, UK; Beckman 
Coulter, USA). Transferosomal colloidal dispersions were diluted with 
pure water before measurement [10].
Transferosome entrapment efficiency (%EE) of lynestrenol
From the two transferosome formulas each, 1 ml from each was 
centrifuged at 10,000 rpm for 1 h (4°C) to allow the separation of the 
unentrapped drug. One milliliter of transferosome was added to 1 mL 
of Triton X (0.1%) and centrifuged at 10,000 rpm for 1 h (4°C) to allow 
the separation of the total drug. After removal of the supernatant, 
the supernatant was added to methanol and then analyzed by high-
pressure liquid chromatography (HPLC) at 204 nm using an HPLC 
system (Shimadzu, Jepang) [11]. The %EE of MIC in the prepared 
transferosome was calculated applying the following equation:
% EE 







Formula F2 without pausing during sonication resulted in the smallest 
particle size of 443.90 nm [Fig. 1]. Sonication crossings were paused and 
not paused. Based on this, the results indicated that sonication without 
pausing resulted in a smaller size. This change was due to the energy 
obtained when sonication was not lost. Sonication with pausing caused 
the energy to disappear so when the sample is resonicated, it took time 
to produced energy to reduce the particle size. In formula F1_P and 
F2_P both F1_WP F2_WP, an increase in the concentration of Tween 80 
resulted in a smaller size than the particle size of F2_P (558.10 nm).
This may be related to the general concept that using surfactants with 
lower hydrophilic-lipophilic balance (HLB) results in the preparation 
of smaller sized vesicles. Therefore, transferosome prepared with 
Tween 80 which is a hydrophilic surfactant, with small concentrations 
of Tween 80 (F1P) has smaller sizes than those prepared with higher 
concentrations. The direct proportionality between vesicle size and 
the HLB of the surfactant can be explained by the reduction in surface 
free energy resulting from high hydrophobicity. The same explanation 
applies to decreases in vesicle size with increases in the total lipid 
content. Formulas F3 and F4 either paused or not paused produced 
larger sized vesicles than FI and F2. The increased vesicle size of 
transferosomes made using F3 is because the cholesterol stiffens the 
transferosome which makes reducing the size more difficult. The lack 
of Tween 80, which is an edge activator, in the F4 formula results 
in reduced flexibility of the vesicles in response to sonication and 
increased vesicle size.
Formulas F3 and F4 either paused or not paused produced a larger 
size vesicle than either FI or F2; this is because the effect of cholesterol 
on the structure of the transferosome became stiff so that reducing 
the size became more difficult. The F4 formula was only composed 
of phospholipids, so the structure of the transferosome was only the 
main constituent of the lipid bilayer and there was no edge activator-
like Tween 80 which was flexible so that when reducing the size with 
sonication was more difficult [12].
As shown in Table 2, all the formulas have negative zeta potentials. 
Negative values of the zeta potential are mainly due to the presence of 
ionic nitrogen atoms in the structure of lynestrenol.
The magnitude of the zeta potential in all of the formulations was high 
enough to provide stability for the vesicles and to prevent coagulation.
The effect of sonication without pauses showed better results in F1_WP 
and F2_WP formulas ranging from −23.80 mv to −18.52 mv (F1_WP) and 
−31.36 mv to −15.98 mv. In this formula, the increased concentration of 
Tween affects the coagulation of the transferosome. The zeta potential 
for the F3_P formula ranged from −31.36 mv to −50.20 mv, which is 
likely due to the presence of cholesterol. The increased zeta potentials 
of F4 are likely due to the vesicle being composed fully of a phospholipid 
bilayer [Fig. 2].
Table 1: The formulas of lynestrenol transferosome
Ingredients Concentration (%)
F1 F2 F3 F4
Lynestrenol 300 mg 300 mg 300 mg 300 mg
Phospholipon 90G 9 8 9 10
Tween 80 1 2 - -
Cholesterol - - 1 -








Fig. 1: Particle size of four formulas. Note: F1 (phospholipid:Tween 80 9:1), F2 (phospholipid:Tween 80 8:2), F3 
(phospholipid:cholesterol 9:1), F4 (phospholipid:Tween 80 10:0) P: paused; WP: Without paused
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CONCLUSION
Nano-transferosomes of the desired size, zeta potential, and entrapment 
efficiency were successfully prepared for transdermal lynestrenol 
delivery. The effect of sonication without pauses gives better results 
on the nature of transferosome compared to sonication with pauses. 
The effect of Tween 80 on the transferosome structure could reduce the 
size, zeta potential, and absorption efficiency. Cholesterol in the lipid 
bilayer transferosome structure made the structure stiff so that the 
properties of the vesicles are less desirable compared to those made 
using Tween 80.
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Table 2: Polydispersity and zeta potential of transferosome formulations
Time (h) Polydispersity
F1_P F2_P F3_P F4_P F1_WP F2_WP F3_WP F4_WP
30 0.655 0.603 0.494 0.838 0.816 0.441 0.494 0.838
60 0.766 0.874 0.937 0.814 0.550 0,717 0.556 0.850
90 0.598 0.598 0.672 0.878 0.677 0.513 0.443 0.710
120 0.692 0.763 0.54 0.437 0.934 0.934 0.763 0.269
Zeta potential (mv)
0 −23.8 −21.86 −31.36 −40.46 −23.80 −21.86 −31.36 −40.46
30 −21.74 −20.64 −44.63 −40.26 −22.14 −19.87 −44.63 −40.26
60 −20.41 −18.71 −49.50 −49.30 −20.78 −16.87 −42.73 −49.30
90 −18.76 −18.03 −39.4 −46.26 −19.41 −16.01 −39.97 −39.3
120 −17.98 −16.25 −50.20 −42.26 −18.52 −15.98 −47.00 −40.20
Fig. 2: Transferosome entrapment efficiency. Note: F1 (phospholipid:Tween 80 9:1), F2 (phospholipid:Tween 80 8:2), 
F3 (phospholipid:cholesterol 9:1), F4 (phospholipid:Tween 80 10:0), P: Paused; WP: Without paused
